Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02979210 · ClinicalTrials.gov registry record · NA
Infant Fecal Insult Study
A NA study of Dermatitis, sponsored by Kimberly-Clark Corporation.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02979210: Completed NA study of Dermatitis, sponsored by Kimberly-Clark Corporation.
NCT02979210 is a NA study of Dermatitis that has completed, run by Kimberly-Clark Corporation. The registered enrollment target is 24 participants, below the 175-participant average among 6 other Dermatitis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02979210, a NA study of Dermatitis, has completed, sponsored by Kimberly-Clark Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The rationale for the study is to better understand the dynamics of skin microflora following skin barrier disruption in an adult dermatitis model. The results from this study will provide insights in the complex interaction between skin microbiome and epidermis under normal and disease conditions
Primary Outcome
Microbes will be identified by metagenomic sequencing
Conditions Studied
Interventions
- OTHER Artificial Fecal Insult
- OTHER Phosphate Buffered Saline
Study Locations (1)
Texas
- Reliance Clinical Testing Service - Irving
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-02-01 |
| Phase | NA |
What the finished NCT02979210 record still lists
NCT02979210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 175-participant average among 6 other Dermatitis trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Artificial Fecal Insult is the first listed.
NCT02979210 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02979210 about?
NCT02979210 is a clinical study titled "Infant Fecal Insult Study". The rationale for the study is to better understand the dynamics of skin microflora following skin barrier disruption in an adult dermatitis model. The results from this study will provide insights in the complex interaction between skin microbiome and epidermis under normal and disease conditions
What is the current status of trial NCT02979210?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2016-11. Estimated completion is 2017-02-01.
What conditions does trial NCT02979210 study?
This clinical trial studies the following conditions: Dermatitis.
What interventions are being tested in trial NCT02979210?
The interventions under investigation include: Artificial Fecal Insult (OTHER), Phosphate Buffered Saline (OTHER).
Who is sponsoring clinical trial NCT02979210?
This trial is sponsored by Kimberly-Clark Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02979210 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating for Contact Allergies in Patients With Chronic Urticaria
COMPLETED
-
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
COMPLETED
-
A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis
COMPLETED · Phase 2
-
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia